How DSO Deal Structures Have Changed

For years, selling to a Dental Support Organization meant a fairly simple conversation: a multiple of EBITDA, a check at closing, and a handshake on staying on for a while. That version of the deal is largely gone. Today’s DSO transactions are layered, negotiated instrument by instrument, and increasingly shaped by state regulation as much as by the buyer’s appetite. If you’re weighing an offer — or expect one in the next few years — understanding how the structure itself has evolved matters as much as the headline number.

From a Single Check to a Blended Package

Most DSO deals today are built from several pieces working together rather than one lump-sum payment:

• Cash at close — still the largest share of most deals, but rarely the whole picture anymore.
• Rollover equity — an ownership stake in the DSO platform (or in a joint-venture entity tied to your specific practice) instead of cash. In many current structures, this isn’t optional; it’s baked into the offer.
• Earnouts — additional payments tied to hitting performance targets, typically EBITDA or production, over a period of one to three years after close.

The mix between these pieces — and the order in which they pay out — now does as much to determine your real take-home as the multiple you’re quoted. Two offers with the same headline number can land very differently in your bank account depending on how much of that number is guaranteed cash versus equity you’re betting on, or income you have to earn.

Equity Is Doing More Work

Rollover equity has moved from a nice-to-have to a central design feature. Sellers are increasingly asked to choose between structures that give them a direct stake in their own practice’s future performance versus a stake in the broader platform — each with a different risk and reward profile. A stake tied to your own practice tends to offer more predictability; a stake in the larger platform offers more upside if the platform grows or eventually recapitalizes, but less control over the outcome.

This shift also has tax implications. Proceeds structured as long-term capital gains — as much rollover equity is — are often taxed at meaningfully lower rates than ordinary income, which is one reason buyers lean on equity components rather than simply raising the cash multiple.

Earnouts: More Common, More Contested

Contingent payments tied to future performance are now a standard deal component rather than an exception. They can work well when targets are realistic and clearly defined — but they’re also one of the most frequent sources of disagreement after closing. Vague overhead allocations, added corporate costs that eat into EBITDA, or “cliff” structures where missing a target by a small margin forfeits the entire payment are common friction points. Sellers who don’t scrutinize how an earnout is calculated — not just what it targets — are the ones most likely to be surprised later.

Longer Commitments, Not Just Bigger Checks

Buyers are also asking for more time. Multi-year employment or retention agreements — often five years or more — are becoming a standard expectation rather than a negotiating point, particularly for practices where the seller is central to production or patient relationships. That commitment is worth weighing on its own terms, separate from the financial structure: it shapes your day-to-day life for years after the transaction closes.

Regulation Is Now Part of the Structure Conversation

Deal structures aren’t only shaped by what buyers want to offer — they’re increasingly shaped by what state law allows. A growing number of states are tightening rules around the corporate practice of dentistry, limiting how much operational control a management company can exercise over an affiliated practice, and in some cases adding notice or review requirements before a deal can close. These rules don’t typically change your price, but they do change what a buyer can legally offer and how long the process takes — which is why the same DSO’s structure can look different from state to state.

What This Means If You’re Considering a Sale

The practical takeaway is that “structure literacy” now matters as much as valuation literacy. Before comparing offers — let alone signing a letter of intent — it’s worth understanding exactly how much of a proposed deal is guaranteed versus contingent, what the equity component actually represents, how an earnout is calculated, and what commitments come attached. Two offers that look similar on the surface can carry very different outcomes once you look at how they’re actually built.

If you’re evaluating an offer or want a clearer picture of how a proposed structure compares to current market norms, that’s exactly the kind of side-by-side analysis we help practice owners work through before they commit to anything.

Equity Arbitrage Explained for Practice Owners

If you’ve been approached by a DSO, you’ve probably heard the term “equity arbitrage” thrown around — usually attached to a promise that rolling over part of your proceeds instead of taking all cash could be worth more down the road. It’s not a sales gimmick. It’s a real mechanic behind how consolidation creates value, and understanding it is the difference between evaluating an offer and just trusting one.

The Basic Idea

Equity arbitrage, in simple terms, is the gap between what your practice is worth on its own and what it’s worth once it’s folded into a larger platform.

A single, well-run practice typically sells on its own for somewhere in the range of 5–8x EBITDA. But once that same practice is combined with dozens or hundreds of others under one DSO platform, the platform — not the individual practice — often trades at a meaningfully higher multiple, sometimes into the low-to-mid teens, when the DSO itself is later sold or recapitalized to a larger investor.

That gap between the multiple a single practice sells at and the multiple the combined platform later sells at is the arbitrage. And if you’ve rolled a portion of your proceeds into equity in that platform, you’re no longer just a seller who got paid once — you own a slice of that gap.

Why the Platform Is Worth More Than the Sum of Its Parts

The uplift isn’t arbitrary. A handful of concrete factors typically drive it:

• Diversified risk. One practice depends heavily on one owner, one location, one local market. A platform of a hundred practices doesn’t carry that same single-point-of-failure risk, which makes it more attractive — and more valuable per dollar of EBITDA — to a larger investor.
• Economies of scale. Shared back-office functions, group purchasing power on supplies and equipment, and centralized marketing and scheduling infrastructure all improve margins across the platform in ways a solo practice can’t replicate.
• Growth trajectory. A platform that’s actively acquiring and integrating new practices tells a growth story that a single, mature practice generally can’t — and growth stories command premium multiples.

What This Means for Your Rollover Equity

When a DSO offers a deal that’s part cash and part rollover equity, that equity is typically priced against the platform’s future exit value, not just today’s practice-level multiple. In a favorable structure, that means your rolled equity has real upside built in from day one — the well-known “second bite of the apple” that many practice owners end up valuing as highly as the initial cash payment, sometimes more.

But the arithmetic only works in your favor if a few things hold true:

1. The multiple gap is real and durable. Platform multiples move with market conditions — interest rates, PE fundraising activity, and buyer appetite all affect what a platform eventually sells for. The spread that looks attractive today isn’t guaranteed to hold for the 5–7 years it typically takes to reach a liquidity event.
2. The valuation basis is consistent. Some structures apply a lower multiple to price your rollover equity than the multiple used to value the overall deal. If that happens, you’re effectively buying your equity stake at a markup relative to what the numbers on the term sheet suggest — worth checking closely before you sign.
3. The platform itself is healthy. A heavily leveraged DSO carrying significant debt relative to its EBITDA has less room for error, and less certainty of reaching a strong exit. Equity in a fragile platform is a different bet than equity in a well-capitalized one, even if the headline terms look similar.

The Practical Takeaway

Equity arbitrage is the reason rollover equity can meaningfully outperform straight cash over time — but it’s a bet on the platform’s future, not a guaranteed multiplier. Before treating a rollover offer as “extra” value on top of your cash proceeds, it’s worth understanding the platform’s current multiple, its debt load, its growth plans, and — critically — whether your equity is being priced on the same basis as the rest of the deal.

If you want a clearer read on how a specific offer’s equity component stacks up, that’s exactly the kind of analysis we walk practice owners through before they commit to a structure.

The Associateship-to-Buy-In Math Most Owners Miss

Bringing on an associate with an eye toward an eventual buy-in feels like the safest way to transition a practice. You get to know them clinically, they get to know your patients and staff, and by the time equity actually changes hands, most of the guesswork is gone. The relationship part of that plan usually works. The math behind it is where owners consistently leave value on the table — often without realizing it until the buy-in is already signed.

The Valuation Date Problem

The most common mistake is treating the buy-in price as if it were locked in on day one. In practice, most buy-ins are priced off the practice’s valuation at the time of the buy-in, not at the time the associate was hired. That sounds reasonable until you consider who drove the growth in between.

If your associate spent two or three years building their own patient base, adding production, and helping grow collections, a meaningful share of the increase in practice value between hire date and buy-in date was created by the person who’s about to buy a piece of it. Depending on how the agreement is written, they can end up paying a higher price specifically because of the growth they personally generated — which is fair in some structures and a real cost to them in others. Owners rarely spell out up front which growth the valuation is meant to capture, and that ambiguity becomes a negotiation flashpoint right when trust matters most.

Compensation Is Quietly Doing Part of the Buy-In

During the associateship phase, most associates are paid on a percentage of collections or production — typically in the high-20s to low-30s percent range. That number is set as if the associate were a pure employee. But if the plan has always been a future buy-in, that compensation structure is also shaping the economics of the eventual deal, whether anyone’s accounted for it or not.

An associate compensated below what a true market-rate buy-in track would justify is effectively subsidizing the practice during the associateship years — value the owner captures without it ever showing up in the buy-in price. Conversely, an associate paid a premium to attract them into the pipeline may be getting compensated for equity they haven’t earned yet. Either way, the associateship comp and the buy-in price are connected, and treating them as two unrelated negotiations is how owners end up either overpaying for loyalty or underpricing the eventual sale.

The Minority Discount Nobody Mentions

A 10–20% ownership stake — the typical starting range for a buy-in — is not simply 10–20% of the practice’s full valuation. A minority, non-controlling interest is worth less per dollar of underlying practice value than a majority stake, because the buyer has limited say over major decisions, distributions, and eventual exit timing. That discount is standard in minority-interest transactions generally, but it’s frequently left out of the conversation entirely, leaving the associate to either pay full pro-rata price for a stake with less control, or the owner to unknowingly give away more value than intended when the discount goes unaddressed.

Financing Reshapes the Real Numbers

Most associate buy-ins aren’t paid in cash up front. They’re financed — often through a combination of practice cash flow distributions, seller financing, or a bank loan collateralized against the associate’s future earnings. Whatever structure is used changes the real economics for both sides:

• Seller-financed buy-ins mean the owner is carrying risk on the associate’s future performance and retention — worth pricing into the terms, not just the headline number.
• Distribution-funded buy-ins, where the associate’s own share of profit pays down their purchase price over time, effectively lower the practice’s near-term cash flow to the owner during the payoff period.
• External bank financing shifts risk off the owner but adds underwriting requirements that can slow or complicate the timeline.

Two buy-ins priced identically on paper can produce very different outcomes for the owner depending on which of these financed the deal.

Second Bites and Future Dilution

Many owner-to-associate transitions aren’t a single buy-in — they’re the first step toward the associate eventually buying out the remaining stake entirely, sometimes years later. If that’s the intent, it’s worth mapping the full sequence now rather than negotiating each step in isolation. The valuation basis, the growth attribution question, and the minority discount all resurface at the second transaction — and if they weren’t handled consistently the first time, they tend to create disputes the second time, right when the relationship needs to hold together most.

The Practical Takeaway

An associate buy-in can be one of the smoothest ways to transition a practice, but the math underneath it is more interconnected than it looks — compensation, valuation timing, minority discounts, and financing structure are all quietly affecting each other, whether or not they’re negotiated together. Getting each piece aligned before the associate joins, not after, is what keeps the eventual buy-in a clean transaction instead of a renegotiation.

If you’re structuring an associateship with a future buy-in in mind — or already mid-way through one — that’s exactly the kind of structure review we help owners work through before the numbers get set.

Kyle Francis on Building a Transition Team Early

Most practice owners don’t think about assembling a transition team until they’re already holding an offer. PTS Founder and President Kyle Francis has spent two decades on both sides of dental M&A, and his advice on this point is consistent: by the time an offer is on the table, it’s already too late to build the team that should have been shaping your decisions for the past year or two.

Why “Early” Means Before You’re Ready to Sell

The instinct for most owners is to treat a transition team as something you hire once you’ve decided to sell. Francis’s view runs the other direction — the team should be in place well before that decision is final, because the choices that determine your outcome (how the practice is structured, how clean your financials are, what your lease looks like, how dependent the practice is on you personally) all need lead time to fix. Waiting until you’re in active negotiations means you’re managing those issues under deal pressure instead of on your own timeline.

Who Actually Belongs on the Team

A full transition team is smaller than most owners expect, but each seat does distinct work that the others can’t cover:

• A transaction-focused CPA. Not your everyday tax preparer — someone who understands how EBITDA normalization, addbacks, and entity structure affect what a buyer will actually offer, and who can get your financials into a state that survives diligence without last-minute scrambling.
• A healthcare transaction attorney. Practice sale agreements, non-competes, employment terms, and (increasingly) state corporate-practice-of-dentistry rules require someone who works in this specific area regularly, not general business counsel.
• A wealth or financial advisor. Especially relevant when a deal includes rollover equity or an earnout — someone who can model what the proceeds actually mean for your retirement and tax picture before you sign, not after.
• An M&A advisor or broker. Someone who runs a structured, competitive process rather than negotiating a single unsolicited offer in isolation — which is consistently where the largest gaps in final outcome show up.

The Cost of Assembling It Late

When these advisors are brought in only after an offer arrives, they’re reacting to a deal someone else designed instead of helping shape one. Financials that needed six months of cleanup get diligenced as-is. Lease terms that could have been renegotiated a year earlier become a liability discovered mid-process. And owners frequently end up accepting the first structure presented simply because there wasn’t time — or a team in place — to compare it against anything else.

Starting the Process on Your Terms

The owners who get the best outcomes, in Francis’s experience, aren’t necessarily the ones with the biggest practices — they’re the ones who treated the 12 to 24 months before a transition as preparation time rather than downtime. That window is when a transition team earns its value: cleaning up the story your financials tell, addressing owner-dependence, and making sure that whenever the right offer does show up, you’re evaluating it from a position of readiness rather than reacting to it cold.

If you’re starting to think about a transition — even years out — that’s exactly the conversation our team at PTS is built to have early.

What Private Equity Really Wants From Your Practice

Most owners prepare their practice for sale the way they’d prepare it for a doctor-to-doctor buyer: clean up the schedule, make sure production looks good, maybe repaint the waiting room. Private equity-backed buyers are looking at something different entirely. They’re not buying a practice the way a colleague would — they’re buying a cash-flowing asset that has to fit into a larger platform’s economics. Understanding what they actually evaluate changes how you prepare, and often what you’re worth.

They’re Buying EBITDA, Not Collections

The biggest mental shift owners need to make: PE-backed buyers don’t value a practice as a percentage of collections the way an individual dentist buyer typically does. They value it as a multiple of normalized EBITDA — profit after replacing your owner’s compensation with a market-rate associate salary. Two practices with identical collections can be worth very different amounts once EBITDA is calculated, because expense discipline, overhead, and how much of the practice’s production genuinely happens without you determine the real number a PE buyer is pricing.

This is also why “cleaning up the financials” isn’t just an accounting exercise before a sale — it’s often the single highest-leverage thing an owner can do, because add-backs and normalization directly move the number the entire deal is priced on.

Owner Independence Matters More Than Owner Talent

A practice that runs beautifully because you personally hold it together is, paradoxically, less attractive to a PE buyer than a slightly less polished practice that would keep functioning if you took a month off. Institutional buyers are underwriting a business, not acquiring your personal skill — a highly owner-dependent practice reads as risk, because the platform’s return depends on the practice performing after you’ve stepped back into a reduced clinical role or left entirely.

Associate depth, delegated case acceptance, a strong clinical team, and documented systems all signal that the value lives in the practice, not exclusively in you. That signal is worth real money in how a PE buyer prices the deal.

Recurring, Hygiene-Driven Revenue

A large share of a dental practice’s most valuable EBITDA comes from routine hygiene visits rather than one-off procedures, because that revenue is predictable and recurs on a schedule. PE buyers place a real premium on strong hygiene conversion and recall systems — not because hygiene is glamorous, but because predictable, recurring cash flow is exactly what an institutional buyer underwrites confidently. A practice heavily reliant on episodic, high-ticket procedures looks riskier on a cash-flow basis, even if the top-line numbers are similar.

Platform Fit, Not Just Practice Quality

A well-run practice can still be a poor fit for a specific buyer if it doesn’t fit their platform strategy. PE-backed DSOs are typically building density in particular geographies, targeting specific specialties, or looking for a certain size tier to make their acquisition and integration model work. A practice can be excellent on every operational metric and still draw limited interest from a buyer whose platform simply isn’t built around your market or your size — which is part of why running a competitive, multi-buyer process tends to surface offers that a single unsolicited inquiry never would.

Transferable Systems and a Clean Story

Beyond the numbers, PE buyers are underwriting how easily the practice integrates: modern practice management software, a documented team structure, a lease with real runway left on it, and a patient base that isn’t concentrated in a handful of relationships that could walk when ownership changes. Every piece of friction a buyer anticipates in integration gets priced into the offer — sometimes as a lower multiple, sometimes as a larger holdback or earnout tied to retention.

The Practical Takeaway

Private equity isn’t evaluating your practice the way you built it — it’s evaluating whether your practice’s cash flow, structure, and growth trajectory will perform reliably inside a much larger platform, with or without you at the center of it. Practices that get the strongest offers are usually the ones that started addressing owner-dependence, financial normalization, and hygiene systems well before a buyer ever walked through the door — not the ones that just have good production numbers.

If you want a clearer sense of how a PE-backed buyer would actually price your practice today, that’s the exact kind of assessment we walk owners through before they’re ever in a negotiation.

Why Dental Consolidation Isn’t Slowing Down in 2025

Every year or two, someone predicts dental consolidation is about to cool off — regulatory pressure, high interest rates, market saturation, take your pick. And every year, the deal volume tells a different story. 2025 has been no exception. After a real pullback in 2023 and 2024, private equity activity in dentistry came back in force this year, and the forces driving it aren’t temporary.

The Slowdown Was Real — And It’s Over

It’s worth acknowledging the dip actually happened. Higher interest rates through 2023 and 2024 made leveraged acquisitions more expensive, and platform-level DSO deals — the large, headline-grabbing roll-ups — genuinely slowed. But tuck-in acquisitions, where an existing DSO absorbs individual practices into its platform, never really stopped; they continued through that period at steady valuations, quietly keeping the consolidation trend alive even while the big deals paused. As rates eased and capital loosened up again, that quieter activity turned back into visible momentum, with dental groups posting some of the most active deal months in recent memory.

The Underlying Pressures Haven’t Gone Anywhere

Interest rates move in cycles. The forces actually pushing independent practices toward consolidation are structural, and none of them reversed:

• Rising overhead and labor costs. Staffing shortages and wage pressure have made the back-office efficiencies a DSO platform offers — group purchasing, shared administrative staff, centralized recruiting — more valuable, not less.
• Reimbursement pressure. Flat or shrinking insurance reimbursement rates squeeze margins for independent owners in a way that scale can partially offset.
• The technology bar keeps rising. Modern imaging, practice management systems, and increasingly AI-assisted clinical and administrative tools require capital investment that’s easier to justify across a platform of practices than for a single office.
• A demographic wave of retiring owners. A large cohort of practice owners is approaching retirement age at the same time buyer demand remains high, keeping deal flow steady from the supply side as much as the buyer side.

None of these pressures are cyclical the way interest rates are. They’re the reason nearly every industry observer expects the long-term trend toward scale to continue well past 2025, even as the pace of any single year fluctuates.

Where the Money Is Actually Going Now

What’s changed isn’t whether private equity is interested in dentistry — it’s where that interest is pointed. The largest national platforms have largely finished building out their footprints, so investor appetite has shifted toward smaller, regional DSOs and platform-building opportunities rather than another round of mega roll-ups. For an owner running — or considering building — a smaller multi-location group, that’s a meaningful opening: a well-run regional platform with clean financials and a differentiated patient base is drawing serious investor interest precisely because the biggest names have already been consolidated.

Specialty dentistry is following its own version of this trend, with oral surgery, orthodontics, and other specialty categories continuing to attract dedicated investor attention and often commanding premium multiples over general dentistry.

Regulation Is Shaping the Deals, Not Stopping Them

States have been paying closer attention to how DSOs structure their relationships with affiliated practices, with several expanding enforcement around corporate-practice-of-dentistry rules. That scrutiny is real and it’s changing deal structure — how much operational control a management company can hold, what notice requirements apply before a deal closes. But it hasn’t reduced the volume of transactions happening; it’s made structuring them correctly a more important part of the process than it was a few years ago.

What This Means If You’re Watching From the Sidelines

The version of consolidation happening in 2025 looks different from 2021’s rapid roll-up era — more disciplined, more focused on smaller platforms, more attentive to regulatory structure — but it is not a slowdown in any way that changes the underlying trajectory. The pressures pushing independent practices toward some form of affiliation or sale are structural, not cyclical, which means the window for owners to transition on their own terms, rather than reactively, keeps getting more relevant rather than less.

If you’re trying to figure out where your practice fits into this environment — whether that means selling now, building toward a future transition, or just understanding your options — that’s exactly the conversation we help owners have.